|
92
|
327
|
5yieA |
Crystal structure of kni-10742 bound plasmepsin ii (pmii) from plasmodium falciparum |
|
98
|
389
|
5ygxA |
Structure of bace1 in complex with n-(3-((4r,5r,6s)-2-amino-6-(1,1-difluoroethyl)-5-fluoro-4-methyl-5,6-dihydro-4h-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide |
|
99
|
387
|
5uyuA |
Crystal structure of bace1 in complex with 2-aminooxazoline-3-azaxanthene compound 12 |
|
81
|
376
|
5bwyA |
Structure of proplasmepsin ii from plasmodium falciparum, space group p43212 |
|
112
|
427
|
4zl4A |
Plasmepsin v from plasmodium vivax bound to a transition state mimetic (wehi-842) |
|
81
|
330
|
4ze6A |
Endothiapepsin in complex with fragment b39 |
|
83
|
330
|
4ycyA |
Endothiapepsin in complex with fragment 218 |
|
98
|
334
|
4ybfA |
Aspartic proteinase sapp2 secreted from candida parapsilosis at 1.25 a resolution |
|
81
|
330
|
4er2E |
The active site of aspartic proteinases |
|
99
|
386
|
4exgA |
Design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors |
|
80
|
330
|
4er1E |
The active site of aspartic proteinases |
|
99
|
386
|
4ewoA |
Design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors |
|
99
|
387
|
4dpfA |
Bace-1 in complex with a hea-macrocyclic type inhibitor |
|
65
|
330
|
4er4E |
High-resolution x-ray analyses of renin inhibitor-aspartic proteinase complexes |
|
97
|
387
|
4dpiA |
Bace-1 in complex with hea-macrocyclic inhibitor, mv078512 |
|
94
|
388
|
4dvfA |
Crystal structure of bace1 with its inhibitor |
|
94
|
391
|
4dv9A |
Crystal structure of bace1 with its inhibitor |
|
91
|
387
|
4dusA |
Structure of bace-1 (beta-secretase) in complex with n-((2s,3r)-1-(4-fluorophenyl)-3-hydroxy-4-((6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)butan-2-yl)acetamide |
|
106
|
390
|
4djvA |
Structure of bace bound to 2-imino-5-(3'-methoxy-[1,1'-biphenyl]-3-yl)-3-methyl-5-phenylimidazolidin-4-one |
|
101
|
389
|
4d85A |
Crystal structure of human beta secretase in complex with nvp-bvi151 |
|
105
|
390
|
4djuA |
Structure of bace bound to 2-imino-3-methyl-5,5-diphenylimidazolidin-4-one |
|
100
|
391
|
4di2A |
Crystal structure of bace1 in complex with hydroxyethylamine inhibitor 37 |
|
99
|
388
|
4d8cA |
Crystal structure of human beta secretase in complex with nvp-bxd552, derived from a co-crystallization experiment |
|
104
|
390
|
4djyA |
Structure of bace bound to (r)-5-cyclopropyl-2-imino-3-methyl-5-(3-(5-(prop-1-yn-1-yl)pyridin-3-yl)phenyl)imidazolidin-4-one |
|
95
|
388
|
4d83A |
Crystal structure of human beta secretase in complex with nvp-bur436, derived from a co-crystallization experiment |
|
90
|
387
|
4dh6A |
Structure of bace-1 (beta-secretase) in complex with (2r)-n-((2s,3r)-1-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-4-((s)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxypropanamide |
|
104
|
390
|
4djxA |
Structure of bace bound to 5-(3-(5-chloropyridin-3-yl)phenyl)-5-cyclopropyl-2-imino-3-methylimidazolidin-4-one |
|
104
|
390
|
4djwA |
Structure of bace bound to 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3-yl)phenyl)imidazolidin-4-one |
|
101
|
388
|
4d89A |
Crystal structure of human beta secretase in complex with nvp-bxd552, derived from a soaking experiment |
|
99
|
388
|
4d88A |
Crystal structure of human beta secretase in complex with nvp-bxq490 |
|
84
|
327
|
4ckuA |
Three dimensional structure of plasmepsin ii in complex with hydroxyethylamine-based inhibitor |
|
83
|
323
|
4cmsA |
X-ray analyses of aspartic proteinases iv. structure and refinement at 2.2 angstroms resolution of bovine chymosin |
|
104
|
388
|
4b1dA |
New aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain |
|
104
|
388
|
4azyA |
Design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound 10) |
|
102
|
388
|
4b77A |
Aminoimidazoles as bace-1 inhibitors: from de novo design to ab- lowering in brain |
|
87
|
323
|
4aucA |
Bovine chymosin in complex with pepstatin a |
|
102
|
384
|
4b78A |
Aminoimidazoles as bace-1 inhibitors: from de novo design to ab- lowering in brain |
|
100
|
385
|
4b70A |
Aminoimidazoles as bace-1 inhibitors: from de novo design to ab- lowering in brain |
|
95
|
390
|
4bekA |
Crystal structure of bace-1 in complex with chemical ligand |
|
101
|
388
|
4b1eA |
New aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain |
|
102
|
390
|
4bfdA |
Crystal structure of bace-1 in complex with chemical ligand |
|
101
|
375
|
4b1cA |
New aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain |
|
99
|
384
|
4b0qA |
Lead generation of bace1 inhibitors by coupling non-amidine new warheads to a known binding scaffold |
|
102
|
388
|
4b00A |
Design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound (r)-41) |
|
94
|
384
|
4belA |
Bace2 xaperone complex |
|
103
|
388
|
4b72A |
Aminoimidazoles as bace-1 inhibitors: from de novo design to ab- lowering in brain |
|
99
|
383
|
4bfbA |
Bace2 xaperone complex |
|
102
|
389
|
4b05A |
Preclinical characterization of azd3839, a novel clinical candidate bace1 inhibitor for the treatment of alzheimer disease |
|
68
|
330
|
4apeA |
The active site of aspartic proteinases |
|
84
|
313
|
4aa9A |
Camel chymosin at 1.6a resolution |
